
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in ...
Background Despite the improved clinical outcomes achieved with endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) in hormone receptor–positive/ HER2-negative (HR+/HER2–) advanced breast cancer, few effective therapeutic agents are …